Managers / Q3 2020 · view latest →
Burrage Capital Management LLC
CIK 0001796461 · 314 COMMONWEALTH AVENUE, #4, BOSTON, MA, 02115 · 617-410-4770
Summary
Burrage Capital Management LLC reported $127M in U.S.-listed holdings across 27 positions for Q3 2020.
Its largest position, Epizyme, represents 9.4% of the portfolio.
Compared with Q2 2020, the fund opened 3 new positions and exited 2.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 84.8% · $107M
- Other · 15.1% · $19M
- ADR · 0.1% · $175,000
Quarter-over-Quarter Changes full breakdown →
vs Q2 2020 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| ASSEMBLY BIOSCIENCES INC | NEW | +200.0K | 200.0K | +$3M | $3M |
| TRICIDA INC | NEW | +188.2K | 188.2K | +$2M | $2M |
| CALLIDITAS THERAPEUTICS AB | NEW | +11.0K | 11.0K | +$265,000 | $265,000 |
| AVROBIO INC COM | SOLD OUT | −225.9K | 0 | −$4M | $0 |
| ADVERUM BIOTECHNOLOGIES INC COM | SOLD OUT | −156.0K | 0 | −$3M | $0 |
| ZOGENIX INC | TRIMMED | −30.8K | 39.2K | −$1M | $703,000 |
| AUPHAURINIA PHARMACEUTICALS INC | ADDED | +105.9K | 362.4K | +$1M | $5M |
| G1 THERAPEUTICS INC | TRIMMED | −145.3K | 228.6K | −$6M | $3M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q3 2020
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q3 2021 | $0 | 1 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $100M | 22 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $123M | 27 | May 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $131M | 25 | Feb 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $127M | 27 | Nov 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $143M | 26 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $102M | 31 | May 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $149M | 29 | Feb 14, 2020 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.